We are live on
!
Find out more
RhumbLine Advisers Portfolio holdings
AUM
$117B
1-Year Est. Return
29.66%
This Fund
S&P 500
This Quarter
Est. Return
+6.98%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.91%
AUM
$49.2B
AUM Growth
+$3.24B
(+7.1%)
Cap. Flow
+$512M
Cap. Flow
% of AUM
1.04%
Top 10 Holdings %
Top 10 Hldgs %
15.87%
Holding
2,920
New
16
Increased
1,206
Reduced
1,586
Closed
85
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$23.3M |
| 2 |
Becton Dickinson
BDX
|
+$18.4M |
| 3 |
Amazon
AMZN
|
+$16.1M |
| 4 |
Berkshire Hathaway Class B
BRK.B
|
+$15.4M |
| 5 |
Johnson & Johnson
JNJ
|
+$14.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
BCR
CR Bard Inc.
BCR
|
+$48.1M |
| 2 |
LVLT
Level 3 Communications Inc
LVLT
|
+$27.7M |
| 3 |
KITE
Kite Pharma, Inc.
KITE
|
+$10.7M |
| 4 |
PRXL
Parexel International Corp
PRXL
|
+$10.3M |
| 5 |
CELG
Celgene Corp
CELG
|
+$10.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 16.9% |
| 2 | Technology | 16.24% |
| 3 | Healthcare | 13.01% |
| 4 | Industrials | 10.83% |
| 5 | Consumer Discretionary | 9.6% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
VIA
2726
DELISTED
Via Renewables, Inc. Class A Common Stock
VIA
| $137K | ﹤0.01% |
2,209
-412
| -16% | -$27.1K |
|
|
XRN
2727
Chiron Real Estate Inc
XRN
$516M
| $135K | ﹤0.01% |
3,284
-485
| -13% | -$21.7K |
|
|
NWHM
2728
DELISTED
THE NEW HOME COMPANY INC.
NWHM
| $135K | ﹤0.01% |
10,789
-2,000
| -16% | -$23.4K |
|
|
JNCE
2729
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
| $134K | ﹤0.01% |
+10,492
| New | +$154K |
|
2730
ImmunityBio
IBRX
$7.8B
| $133K | ﹤0.01% |
29,518
-5,491
| -16% | -$26K |
|
2731
Veracyte
VCYT
$4.77B
| $133K | ﹤0.01% |
20,367
-4,752
| -19% | -$35.3K |
|
|
AMBR
2732
DELISTED
Amber Road Inc
AMBR
| $133K | ﹤0.01% |
18,130
-3,100
| -15% | -$23.1K |
|
|
KEG
2733
DELISTED
Key Energy Services, Inc. Common Stock
KEG
| $133K | ﹤0.01% |
11,298
-2,343
| -17% | -$25.9K |
|
2734
Gaia
GAIA
$46.8M
| $132K | ﹤0.01% |
10,611
-923
| -8% | -$11.4K |
|
2735
Clearfield
CLFD
$420M
| $131K | ﹤0.01% |
10,680
-2,000
| -16% | -$26.9K |
|
2736
Tiptree Inc
TIPT
$655M
| $129K | ﹤0.01% |
21,600
-4,076
| -16% | -$26.6K |
|
|
ITI
2737
DELISTED
Iteris, Inc.
ITI
| $129K | ﹤0.01% |
18,540
-4,202
| -18% | -$28.5K |
|
|
ZYNE
2738
DELISTED
Zynerba Pharmaceuticals, Inc
ZYNE
| $129K | ﹤0.01% |
10,337
-7,252
| -41% | -$83.1K |
|
|
HBP
2739
DELISTED
Huttig Building Products, Inc.
HBP
| $129K | ﹤0.01% |
19,435
-4,256
| -18% | -$28.6K |
|
|
ICD
2740
DELISTED
Independence Contract Drilling, Inc.
ICD
| $128K | ﹤0.01% |
1,607
-279
| -15% | -$20.3K |
|
|
JAX
2741
DELISTED
J. Alexander's Holdings, Inc.
JAX
| $127K | ﹤0.01% |
13,067
-2,562
| -16% | -$26.6K |
|
2742
Build-A-Bear
BBW
$442M
| $126K | ﹤0.01% |
13,736
-2,523
| -16% | -$21.5K |
|
|
MACK
2743
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
| $125K | ﹤0.01% |
15,477
-3,155
| -17% | -$29.4K |
|
|
CLSD
2744
DELISTED
Clearside Biomedical
CLSD
| $124K | ﹤0.01% |
1,177
-278
| -19% | -$29.8K |
|
|
SBBP
2745
DELISTED
Strongbridge Biopharma plc.
SBBP
| $124K | ﹤0.01% |
17,085
-4,771
| -22% | -$29.8K |
|
|
DRRX
2746
DELISTED
DURECT Corp
DRRX
| $122K | ﹤0.01% |
13,265
-3,924
| -23% | -$46.6K |
|
2747
Fortress Biotech
FBIO
$109M
| $121K | ﹤0.01% |
2,018
-631
| -24% | -$37.2K |
|
2748
Information Services Group
III
$197M
| $121K | ﹤0.01% |
28,958
-4,301
| -13% | -$17.9K |
|
2749
Nature's Sunshine
NATR
$357M
| $121K | ﹤0.01% |
10,465
-1,918
| -15% | -$21.8K |
|
|
VIVS
2750
VivoSim Labs
VIVS
$1.35M
| $120K | ﹤0.01% |
374
-93
| -20% | -$34.6K |
|
Similar funds
VAM
RhumbLine Advisers's Q4 2017 Portfolio in Review
As of Q4 2017, RhumbLine Advisers held 2,920 positions worth $49.2B, up 7.1% from $46B the previous quarter. Its ten largest holdings account for 16% of the portfolio.
Trading was light in Q4 2017: portfolio turnover was 3.5%. RhumbLine Advisers opened 16 new positions and exited 85, leaving the 2,920-position portfolio largely intact.
By sector, the portfolio is most concentrated in Financials at 17% of assets, up from 17% a quarter earlier, followed by Technology and Healthcare.
- RhumbLine Advisers's largest Q4 2017 buy was Delphi Technologies PLC Ordinary Shares: 187,382 shares worth $9.83M.
- RhumbLine Advisers added most to Microsoft in Q4 2017, an estimated $23.3M increase.
- RhumbLine Advisers's biggest Q4 2017 reduction was Celgene Corp, cutting an estimated $10.2M.
- RhumbLine Advisers fully exited CR Bard Inc. in Q4 2017, selling an estimated $48.1M.
- RhumbLine Advisers's ten largest holdings make up 16% of its $49.2B portfolio in Q4 2017.
- RhumbLine Advisers opened 16 new positions and closed 85 in Q4 2017.
- RhumbLine Advisers's portfolio value rose 7.1% quarter-over-quarter to $49.2B.
Based on RhumbLine Advisers's 13F filing for Q4 2017, filed 9 Feb 2018.